Navigation Links
12-Month Study Reports Efficacy Rates for AMS' Elevate Apical and Posterior Prolapse Repair System

MINNEAPOLIS, Sept. 21 /PRNewswire/ -- American Medical Systems® (AMS) (Nasdaq: AMMD), a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the results of a 12-month single-arm, prospective multi-center study of the Elevate® Apical and Posterior Prolapse Repair System.  The pelvic organ prolapse quantification exam (POP-Q), used to quantify, describe, and stage pelvic support, was implemented in the study and concluded efficacy rates of Stage 1 or less to be 89.2% for Apical and 91.7% for Posterior.

The results presented at IUGA/ICS meeting also show that 98.4% of patients treated with the Elevate system would recommend the procedure to a friend.  The study was conducted at sixteen centers in the U.S., Canada, Belgium and UK.

Elevate is a minimally invasive, comprehensive solution to treat apical and posterior defects.  The total transvaginal approach is designed to minimize tissue trauma.  Elevate offers safe, simple and precise apical mesh placement in the sacrospinous ligament through a single vaginal incision.

"Our findings indicate that Elevate offers a prolapse repair technique that is safe with low morbidity and minimal postoperative pain," said Dr. James Lukban, principal investigator of the study.  "Our study concluded that Elevate Apical and Posterior is effective in terms of anatomic correction and improvement in day-to-day symptoms at one year, with ongoing analysis through 24 months."

"Over 34 million women worldwide are affected by vaginal prolapse.  This study provides reliable data that can help patients and their doctors make decisions about treatment options to improve quality of life and restore pelvic anatomy," stated John Nealon, senior vice president and general manager of Women's Health at AMS.

The Elevate Apical and Posterior Prolapse Repair System is part of American Medical Systems' comprehensive portfolio of products designed to treat female incontinence and pelvic floor conditions.  For more information about AMS' complete line of female pelvic health solutions, visit

About American Medical Systems:

American Medical Systems, headquartered in Minnetonka, Minnesota, is a diversified supplier of medical devices and procedures to cure stress incontinence, erectile dysfunction, benign prostatic  hyperplasia (BPH), pelvic floor prolapse and other pelvic disorders in men and women.  These disorders can significantly diminish one's quality of life and profoundly affect social relationships.  In recent years, the number of people seeking treatment has increased markedly as a result of longer lives, higher-quality-of-life expectations and greater awareness of new treatment alternatives.  American Medical Systems' products reduce or eliminate the incapacitating effects of these diseases, often through minimally invasive therapies.  The Company's products were used to treat more than 335,000 patients in 2009.

More information about the Company and its products can be found at its website and in the Company's Annual Report on Form 10-K for 2009 and its other SEC filings.

SOURCE American Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
2. 12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
3. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
4. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
5. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
6. Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study at ARVO 2009 Annual Meeting
7. 12-Month Study Reports 90% Success Rate for AMS MiniArc Single-Incision Sling
8. Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA® Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
9. Cardiac Dimensions® Announces Presentation of 12-Month Follow-up Data of TITAN™ Trial at European Society of Cardiology Meeting
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
(Date:12/1/2015)... 1, 2015   Nottingham Spirk , a ... the publication of a free whitepaper , ... Market". The whitepaper gives medical product companies, pharmaceutical ... this lucrative segment. Nottingham Spirk ... manage their own health, save money (i.e., fewer ...
(Date:12/1/2015)... Dec. 1, 2015  Eyeon Therapeutics has received ... eye treatments based on a charged hydrophilic polymer ... CDMO.  The product has been shown to be ... published.  Mark Mitchnick , MD, CEO states, ... to additional polymers in conjunction with a therapeutic ...
(Date:12/1/2015)... Colo. , Dec. 1, 2015 /PRNewswire/ ... ) today announced that its Chief Executive ... at the Oppenheimer Annual Healthcare Conference in ... participate in the conference through a webcast ... , --> ...
Breaking Medicine Technology:
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is a thing of ... greater among Millennials (a whopping one in three aged 18 to 25 is inked). ... dissatisfied with their ink. In fact, RealSelf , the world’s largest community for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot wounds ... Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a health care ... to diseases of the diabetic foot. The American Board of Multiple Specialties ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... facilities, radiographic technicians must mark the film for accurate interpretation by the radiologist. ... of. Fortunately, an inventor from Sacramento, Calif., has found a way to alleviate ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. ... results enhancements at the Radiological Society of North America (RSNA) 2015 annual meeting ...
Breaking Medicine News(10 mins):